SWM
SPRY icon

Spire Wealth Management’s ARS Pharmaceuticals SPRY Stock Holding History

Spire Wealth Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-400
Closed -$3.21K – 2368
2026
Q1 		$3.21K Hold
400
– – ﹤0.01% 1938
2025
Q4 		$4.66K Hold
400
– – ﹤0.01% 1927
2025
Q3 		$4.02K Hold
400
– – ﹤0.01% 2014
2025
Q2 		$6.98K Hold
400
– – ﹤0.01% 1840
2025
Q1 		$5.03K Hold
400
– – ﹤0.01% 2058
2024
Q4 		$4.22K Buy
+400
New +$5.6K ﹤0.01% 2091

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Spire Wealth Management's SPRY Position: Q2 2026 in Review

Spire Wealth Management sold out of ARS Pharmaceuticals (SPRY) in Q2 2026, closing a stake of 400 shares — an estimated $3.21K sold.

Spire Wealth Management first reported a position in SPRY in Q4 2024 and held it in 6 quarters. The position peaked at $6.98K in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Spire Wealth Management reported no remaining ARS Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Spire Wealth Management sold 400 ARS Pharmaceuticals shares in Q2 2026, an estimated $3.21K.
  • Spire Wealth Management first reported a position in ARS Pharmaceuticals in Q4 2024 and held it in 6 quarters.
  • Spire Wealth Management's ARS Pharmaceuticals position peaked at $6.98K in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Spire Wealth Management's 13F filing for Q2 2026, filed 15 Jul 2026.